---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-229770"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-05-19T12:45:19+00:00"
generated_at: "2026-05-19T12:50:53.200464+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate

## Summary
- 60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.
- 89% of patients showed clinical improvement per investigator global impression at week 12; 79% per patient global impression.
- Among 22 patients at 100mg and 300mg BID, no dose discontinuations; 9% had Grade 3+ TRAEs; no rash or stomatitis observed.
- Expansion cohorts opened at 400mg QD and 300mg BID for adults/adolescents; pediatric dose-finding ongoing.
- All 32 enrolled patients remained on treatment as of April 15, 2026 data cut-off; prior alpelisib/sirolimus use in 72%.

## SEC filing metadata
- accession: 0001193125-26-229770
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-05-19T12:45:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/0001193125-26-229770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/rlay-20260519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-229770
- JSON: https://secwatch.observer/filing/0001193125-26-229770.json
- Plain text: https://secwatch.observer/filing/0001193125-26-229770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.